Company intelligence / Profile preview
Oak Hill Bio
Altrincham, Cheshire, United Kingdomoakhillbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Rugonersen showed promising clinical data for Angelman syndrome. OHB-607 showed statistically significant shift towards milder bronchopulmonary dysplasia and positive trend in reducing intraventricular hemorrhage in Phase 2 trial.
- Therapeutic areas
- OphthalmologyPulmonologyNeurology
- Modalities
- Antisense oligonucleotide (ASO)Recombinant protein (IGF-1/IGFBP-3)Plasma kallikrein inhibitor
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Roche (licensed rugonersen)Chiesi Group (license and development agreement for OHB-607)Takeda (acquired pipeline from)
Beyond the preview
Go deeper on Oak Hill Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oak Hill Bio.